Navigation Links
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Date:3/6/2012

id loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways. In April 2011, Ayesha Alvero, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine, presented data at the American Association for Cancer Research Annual Meeting from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the August 2011 issue of Molecular Cancer Therapeutics. In additional pre-clinical studies, ME-344 has demonstrated far superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128.

About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company's lead drug candidates, ME-143 and ME-344, have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and expects to collect final safety and pharmacokinetic data from the trial by June 2012. The Company submitted an Investigational New Drug application for ME-344 in March 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
2. Marshall Edwards Announces Rights Offering to Stockholders
3. Marshall Edwards Adds $2 Million in Private Placement
4. Marshall Edwards Announces $2 Million Private Placement
5. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
6. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
8. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
9. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
10. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
11. Marshall Edwards Announces Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... NOVATO, Calif., Aug. 13 BioMarin,Pharmaceutical Inc. (Nasdaq ... the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3,clinical trial ... of The Lancet.,The study suggests that treatment with ... in some phenylketonuria (PKU) patients.,Kuvan, an investigational oral ...
... Aug. 13 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ... oral presentation at the American Chemical Society National,Meeting ... 21, 2007,at 2:50 p.m. Eastern Time. The presentation, ... levels by enzyme inhibitors for the,potential treatment of ...
Cached Medicine Technology:Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 2Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 3Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 4Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 5Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 2Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 3
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... Recently, BellasDress has launched its ... dresses. BellasDress has chosen their best-selling lace wedding dresses, ... the holiday season. , Now, BellasDress.com features popular ... here at discount prices. The business hopes everyone can ... , “All our elegant products are made ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2
... (RPI) has received a tentative approval from the US FDA ... for initial therapy or with other classes of anti-hypertenive agents. ... of heart failure and patients who do not respond to ... launch the product only in June 2002, when the original ...
... has approved a new method to treat women suffering excessive ... the tissue at fault. Millions of women suffer menorrhagia, benign ... than 20 tampons in a single day. Thousands of women ... try hormone treatment.// ,The other option is to ...
... levels that tend to be slightly elevated but still ... risk for suffering from heart disease. Blood pressure readings ... the first number in a blood pressure measurement, represents ... number, the diastolic value, represents the pressure when the ...
... man has received a self-contained artificial heart, but he ... University Hospital in Philadelphia, Pennsylvania, said. The medical team ... Surgeons have said previously that patients considered for the ... days to live. // ,"The operation went ...
... treating a resistant type of lymphoma, according to a ... many types of cancer cells, so it may be ... Fojo of the National Cancer Institute in Bethesda, Maryland, ... T-cell lymphoma, a cancer of the lymphatic system that ...
... help sort out whether people with aches and coughs have the ... Anthrax victims don't have runny noses. In general, the first symptoms ... wintertime viruses -- fever, ache, cough, no energy. // ... anthrax-killing antibiotics -- which do nothing for colds and flu -- ...
Cached Medicine News:
... Lyphochek Elevated Immunosuppressant Control is a ... whole blood. This unique product is ideal ... very high Cyclosporine levels, such as C2 ... patients at two hours post-dose., ,Lyphochek Elevated ...
Liquichek Hematology-16T Control is a hematology reference control used in monitoring determinations of blood cell values on TOA SYSMEX cell counters....
NEW Liquichek Reticulocyte Control (A)is an assayed whole blood control for evaluating the precision of automated methods of reticulocyte counting....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: